Kyverna Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Except as set forth below, duringthe fiscal quarter ended September 30, 2025, none of our directors or officers (as defined in Section 16 of the Exchange Act)adopted orterminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K.
| Name and Title of Director or Officer | Date Adopted | Type of Arrangement | Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading Arrangement | Duration |
|---|---|---|---|---|
| Karen Walker, Chief Technology Officer | September 12, 2025 | Rule 10b5-1 trading arrangement | Up to 67,997 shares, plus 100% of net shares issued upon vesting of restricted stock units with respect to 20,000 shares on April 11, 2026, after giving effect to shares surrendered or sold to cover withholding taxes | May 1, 2026, or such earlier date upon which all transactions are completed or expire without execution |
| Naji Gehchan, Chief Medical and Development Officer | September 12, 2025 | Rule 10b5-1 trading arrangement | Up to 106,250 shares | April 1, 2026, or such earlier date upon which all transactions are completed or expire without execution |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.